Trial Profile
A retrospective cohort study evaluating safety of telaprevir in combination with pegylated interferon-alfa-2b and ribavirin in patients with genotype 1 chronic hepatitis C
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 25 Jan 2018
Price :
$35
*
At a glance
- Drugs Telaprevir (Primary) ; Peginterferon alfa-2b; Ribavirin
- Indications Hepatitis C
- Focus Adverse reactions
- 25 Jan 2018 New trial record